OncLive
OncLive
  • Видео 16 899
  • Просмотров 8 194 962
Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL
Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with diffuse large B-cell lymphoma (DLBCL).
Patients with DLBCL and central nervous system (CNS) metastases may derive more benefit from CAR T-cell therapy than bispecific antibodies, as more data have been published supporting the use of the former in this population, Maakaron says. For patients...
Просмотров: 40

Видео

Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma
Просмотров 294 часа назад
Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma. Mohamad Mohty, MD, PhD, professor, hematology, Sorbonne University, head, Clinical Hematology and Cellular Therapy Department, Saint-Antoine Hospital, discusses findings from the French compassionate use program evaluating the real-world efficacy of elranatamab-bcmm (E...
Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC
Просмотров 644 часа назад
Joshua Linscott, MD, discusses using urinary cell-free tumor DNA to predict minimal residual disease in high-risk non-muscle invasive bladder cancer.
Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC
Просмотров 324 часа назад
Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.
Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meeting
Просмотров 234 часа назад
David M. O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, director, Division of Gynecologic Oncology, co-director, Gynecologic Oncology Phase I Program, The Ohio State University Comprehensive Cancer Center - James; and Chandler H. Park, MD, FACP, medical oncologist, Norton Healthcare; clinical assistant professor, University of Ke...
Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC
Просмотров 684 часа назад
Website: www.onclive.com Twitter: OncLive Facebook: OncLive/ LinkedIn: www.linkedin.com/company/onclive Neil D. Gross, MD, FACS, surgeon-scientist, director, Clinical Research, professor, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the neoadjuvant use of cemiplimab-rwlc (Libtayo) in the treatment...
Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma
Просмотров 84 часа назад
James Ignatz-Hoover, MD, PhD, hematologist/oncologist, University Hospitals Seidman Cancer Center, discusses the future of treatment with CAR T-cell therapy and bispecific antibodies in patients with relapsed/refractory multiple myeloma. The next generation of CAR T-cell therapies is making significant strides in addressing several critical issues that have arisen in the management of multiple ...
Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer
Просмотров 157 часов назад
David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology, professor, medicine, Medical Oncology, Yale School of Medicine; director, Physician Scientist Training Program, Pathology Research, director, Tissue Microarray Facility, director, Yale Pathology Tissue Services, Pathology, Yale Cancer Center, discusses the primary challenges in distinguishing between HER2-low and HER2-ultralow breast...
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
Просмотров 127 часов назад
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine; executive director, Winship Cancer Institute of Emory University; associate vice president, Cancer, Woodruff Health Sciences Center, and Chandler H. Park, MD, FACP, medical oncologist, Norton Healthcare...
Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC
Просмотров 207 часов назад
Antonio Cigliola, MD, discusses interim efficacy data from the SURE-01 study investigating neoadjuvant sacituzumab govitecan in patients with MIBC. Antonio Cigliola, MD, medical oncologist, IRCCS San Raffaele Hospital, discusses interim efficacy findings from the phase 2 SURE-01 study (NCT05226117) investigating neoadjuvant sacituzumab govitecan-hziy (Trodelvy) in patients with muscle-invasive ...
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL
Просмотров 327 часов назад
Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL. Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School, discusses her decision-making process when considering the use of bispecific antibodies vs CAR T-cell therapy in pati...
Dr McCarthy on Neutrophil-Mediated Immunosuppression in Multiple Myeloma
Просмотров 427 часов назад
Philip McCarthy, MD, discusses findings from an investigation, assessing the impact of neutrophils within the tumor microenvironment of multiple myeloma.
Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma
Просмотров 157 часов назад
Andrew Ip, MD, discusses alternative splicing of the TNFRSF17 gene, which encodes BCMA, in patients with lymphoma or multiple myeloma.
Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E-Mutant mCRC
Просмотров 277 часов назад
Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E-mutated metastatic colorectal cancer. Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in Medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therap...
Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer
Просмотров 327 часов назад
Adrienne G. Waks, MD, discusses efforts to address unmet needs in HER2-positive breast cancer. Adrienne G. Waks, MD, physician, associate director of Clinical Research, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the need for more personalized approaches in the treatment of patients with HER2-positive breast cancer. At the 2024 ASCO Annual Meeting, Wa...
Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma
Просмотров 349 часов назад
Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma
Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCC
Просмотров 259 часов назад
Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCC
Information Overload in Oncology: Episode 1
Просмотров 349 часов назад
Information Overload in Oncology: Episode 1
Dr Arnulf on Patient Factors and Biomarkers that Impact PFS With Ide-Cel in R/R Myeloma
Просмотров 349 часов назад
Dr Arnulf on Patient Factors and Biomarkers that Impact PFS With Ide-Cel in R/R Myeloma
Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD-positive AML
Просмотров 439 часов назад
Dr Erba on the Safety of Quizartinib By Treatment Phase and Age in FLT3-ITD-positive AML
Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC
Просмотров 1112 часов назад
Dr Lenz on Frontline Nivolumab Plus Ipilimumab in MSI-H/dMMR mCRC
Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPC
Просмотров 1612 часов назад
Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPC
Dr Siegel on Real-World Outcomes With Tandem Transplant in Newly Diagnosed Myeloma
Просмотров 2212 часов назад
Dr Siegel on Real-World Outcomes With Tandem Transplant in Newly Diagnosed Myeloma
Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma Management
Просмотров 4512 часов назад
Dr Hauschild on the Role of Adjuvant/Neoadjuvant Therapy in Melanoma Management
Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDAC
Просмотров 1112 часов назад
Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDAC
Dr Tarhini on the Utility of a Prognostic Model in Advanced Melanoma Following ICI Treatment
Просмотров 1512 часов назад
Dr Tarhini on the Utility of a Prognostic Model in Advanced Melanoma Following ICI Treatment
Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL
Просмотров 3014 часов назад
Dr Winter on Unmet Needs in Richter Transformation for Patients With CLL
Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC
Просмотров 7314 часов назад
Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC
Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer
Просмотров 4614 часов назад
Dr Maluf on Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer
Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC
Просмотров 5614 часов назад
Dr Serzan on the Potential of Botensilimab/Balstilimab to Address Unmet Needs in RCC

Комментарии

  • @elizabethbeth9930
    @elizabethbeth9930 День назад

    tamoxifen can cause breast cancer in the other breast !

  • @minismokeshop
    @minismokeshop 2 дня назад

    they make more money when your insurance pays for pills.

  • @Buy_YT_Views_227
    @Buy_YT_Views_227 2 дня назад

    Love it!

  • @alprincmalki
    @alprincmalki 2 дня назад

    I have itching time to time but not after hot shower what does that mean also my hemogolobin is normal but RBC is high

  • @user-tz8pf4pd4q
    @user-tz8pf4pd4q 3 дня назад

    Gaw Dayum this doctor is hawwwwt

  • @ceburockhead
    @ceburockhead 4 дня назад

    for acute gout or arthritis I take DEXA 1 mg for 3 days and its gone , im 65 yrs old male , wt 70 kg

  • @Ripleycat
    @Ripleycat 4 дня назад

    Anastrazole gave me insomnia and nausea. Tamoxifen gives me muscle and bone aches. 65 yr old, DCIS.

  • @TariqKhan-fv1bn
    @TariqKhan-fv1bn 5 дней назад

    I have this please help me

  • @kardste8114
    @kardste8114 6 дней назад

    How do u measure the lean muscle- and Why doesn’t every Cancer clinic do it??

  • @kardste8114
    @kardste8114 6 дней назад

    Is there a Standard of Care regarding Measuring and Tracking cancer cachexia?

  • @richle905
    @richle905 9 дней назад

    You have to spend a lot on your education to try to sound intelligent while saying something this stupid.

  • @khaliddurrani6432
    @khaliddurrani6432 10 дней назад

    BCLC has revised its guidelines whereby resection is an option for single tumor any size in child A patients without any evidence of portal hypertension. Eastern centres in Japan, Korea, China have their own criteria for resection that is not as restrictive as BCLC ( intermediate stage )

  • @trevordaviesable
    @trevordaviesable 13 дней назад

    My wife has leukaemia, I am looking for help via epigenetic possibilities . What possibilities are there particularly regarding diet but also in any avenue of possibility?

  • @annayoung6050
    @annayoung6050 14 дней назад

    I have been on herceptin for six years,I am ok with the treatment my question is just how long can I stay on this,as my ct scans are good I am 84years old

  • @beeftekproduction9380
    @beeftekproduction9380 15 дней назад

    Normal ferritin but low hepcidin. Some days i get 2000+ extracystoles.

  • @Jobobasdhascy
    @Jobobasdhascy 17 дней назад

    Where do you get this in NZ

  • @shizuoka4232
    @shizuoka4232 17 дней назад

    Thank you

  • @SJ-wu9gx
    @SJ-wu9gx 17 дней назад

    Isnt regorafenib more effective in vegf cancers like peritoneum mets

  • @dehilakisuki8150
    @dehilakisuki8150 18 дней назад

    Everybody need to know that herbs is healthy, natural and powerful. My sister got cured of high risk Human Papillomavirus with a herbal medicine she bought and used from *DR MADIDA* on RUclips. I recommend Dr Madida to everyone because he has really being helpful to me and our family at large🤗😊🎉.

  • @Nisha-kl8rl
    @Nisha-kl8rl 20 дней назад

    For anyone dealing with ITP, Planet Ayurveda's treatment is the best. Their holistic approach really works.

  • @Nisha-kl8rl
    @Nisha-kl8rl 20 дней назад

    Planet Ayurveda has the best treatment for ITP. My overall health has greatly improved since starting their regimen.

  • @Nisha-kl8rl
    @Nisha-kl8rl 20 дней назад

    Planet Ayurveda’s ITP treatment has given me the best results. I can’t recommend them enough.

  • @Rene-uz3eb
    @Rene-uz3eb 22 дня назад

    More than one chelator at same time works even better (edta, alb)

  • @user-fo2cc7xx4y
    @user-fo2cc7xx4y 25 дней назад

    Why aren't oncologist giving mtor inhibitors for cancer? My mom is stage 4 . Will inhibting this slow tumor growth???😊

  • @thebeardedtuckfardo6168
    @thebeardedtuckfardo6168 28 дней назад

    i have this cancer, this doesnt make me feel like treatment is worth it, already did 18 weeks of it and been hospitalized for sepsis from cisplatin. but im a fighter so im going to fight it. just dont like hearing these kinda options.

  • @williamgriffin2132
    @williamgriffin2132 28 дней назад

    Ps I had all that had prostate cancer and they gave me Harmon treatment's

  • @mohinichavan7943
    @mohinichavan7943 28 дней назад

    Very good knowledge ❤

  • @Freakyneeks13
    @Freakyneeks13 Месяц назад

    Complicated disease.

  • @SampathDisanayaka-vp6wb
    @SampathDisanayaka-vp6wb Месяц назад

    IlovE uou

  • @adrianmedeea486
    @adrianmedeea486 Месяц назад

    For almost a year had Herpes and I was lonely and sad luckily I was directed to a very kind and Great DRALLENBEN who helped me cure my Herpes and today I am free from Herpes and healthy…… ☘️☘️☘️🍁🌸🍀

  • @alexanderrose-young1873
    @alexanderrose-young1873 Месяц назад

    What's the song in the background? 😊

  • @jamesscott1189
    @jamesscott1189 Месяц назад

    With prostate cancer, on Zytiga for 4 yrs. Lost sex drive in 6 mos. Energy down but stable. Quit working at 4 yrs 3 mos. Tried Erleada, no good. Now beginning chemo, age 81, male.

  • @q95oldies57
    @q95oldies57 Месяц назад

    Some rough side effects. I've been on it for 18 months. Aching muscles, joints, fatigue, minor hot flashes, just feeling weird.

  • @yamaha1675
    @yamaha1675 Месяц назад

    I have HH and have give phlebotomy for years. Now for a while my ferratin is 12 and all my iron levels are low. I feel absolutely terrible and am 49 years old. Is iron infusion safe? I wouldnt think so but not a doc!

  • @FayRaf-zq5om
    @FayRaf-zq5om Месяц назад

    never knew talking about cancer could be full of so much laughter and fun - i will try to remain in similar humorous mood at next chemo session!!

  • @PriscaLunga
    @PriscaLunga Месяц назад

    Hie my name is Prisca I was diagnosed with cancer 2021, lymphoma I did have my chemotherapy sections at Mpilo hospital in Zimbabwe but I have run out of funds to finish with my treatment,I have to do a CT scan so that they know how the medication is working, please I need ur help I don't work

  • @edithflores9476
    @edithflores9476 Месяц назад

    Y

  • @edithflores9476
    @edithflores9476 Месяц назад

    You are the best

  • @melaniepitt4295
    @melaniepitt4295 Месяц назад

    I have been on pembrolizumab and lenvatinib for nearly four months and have had to have dose reductions from 20mg to 8mg due to peripheral neuropathy which I contracted after chemotherapy two years ago, effecting my balance and strength plus extreme fatigue. I am concerned about only taking the minimum dose as from all I have researched online, 14mg is the lowest recommended. My doctors are concerned about my quality of life and asked me if I want to stop the treatment. As I can still look after myself, drive and on a good day, ride my horse, I will continue for now.

  • @Arateenteras
    @Arateenteras Месяц назад

    Interesting, though very little mention to the toxicity versus improvement of duration ,in months.I feel this should be a must in the conversation.Feels the way is treated it hasn’t lost completely humanitarian site ..versus “the improvement” I say as a cancer patient.Its despairing to listen, in spite of the interest and effort.Finally as “lab rat “ stage 4 that I am it would be nice that they contemplate this aspect as essential

  • @tammywade3649
    @tammywade3649 Месяц назад

    I take low dose aspirin, my white cells and platelets are high

  • @andersonsprairieviewfarm2552
    @andersonsprairieviewfarm2552 Месяц назад

    When I think of grains, I think of herbicides and pesticides and cancer.

  • @evefairy7740
    @evefairy7740 Месяц назад

    the damn thing is rising not from anal sex increase among hetero population, but because of damn haemorrhoid steroid creams and haem operations which reactivate HPV , anal dysplasia ....causing anal cancer! deception deception and deception- to make business from human health and lives

  • @belab9741
    @belab9741 Месяц назад

    Respected Sir im dijagnosed with GCT please can i contacted you on your email please

  • @yaminiayachitam
    @yaminiayachitam Месяц назад

    I think these doctors and scientists only care if the patient is alive, they don't care about the quality of life. Immunotherapy can deteriorate a patient's everyday life by worsening liver cirrhosis. They need to give full side effects and what are risk factors in complete detail before making any videos promoting immunotherapy

  • @robertacarroll8481
    @robertacarroll8481 Месяц назад

    Very interesting

  • @user-zi4ix6dk8o
    @user-zi4ix6dk8o Месяц назад

    BANG

  • @edivaniapereira9670
    @edivaniapereira9670 Месяц назад

    Oi

  • @SicilianStealth
    @SicilianStealth Месяц назад

    I was just diagnosed.

  • @dr.tanveerahmedph.d4176
    @dr.tanveerahmedph.d4176 Месяц назад

    The cost of cancer care is a topic at the center of a national discourse on fiscal responsibility and resource allocation. According to the Centers for Medicare and Medicaid Services, national health expenditures as a percentage of the U.S. gross domestic product (GDP) totaled 5% in 1965, but are expected to total 20% of GDP by the middle of this decade [1]. Although spending on cancer care comprises only 5% of the overall health care budget [2], these costs continue to rise at a pace more rapid than any other area of health care [3]. National cancer expenditures are projected to increase from $125 billion in 2010 to $173 billion in 2020 [4]. As an increasing number of expensive targeted therapies are adopted as standards of care, the average cost of treating common cancers is rising rapidly, with drugs accounting for approximately 40% of the overall cost of cancer care [1]. Another area of increasing costs is the use of diagnostic imaging. Significant annual increases in imaging have occurred across all major cancer types, and imaging costs have been rising at a faster rate than average total costs of care [5]. As a sequela of these rising expenditures, patients are shouldering an increasing proportion of the health care cost burden, often placing them under significant financial stress. Treatment-related costs have been shown to significantly increase financial burden among underinsured patients [6]. As we struggle to control rising national cancer expenditures, oncology providers are forced to examine practice patterns and their contributions to the overall health care cost burden. In 2010, Dr. Howard Brody presented a challenge to the leaders of all medical subspecialties to devise “top five” lists of costly treatments or diagnostics that lack the evidence base to support common use [7]. In response, the American Board of Internal Medicine has promoted the Choosing Wisely campaign, encouraging physicians to choose tests and treatments that are grounded in a solid evidence base. The American Society for Clinical Oncology, along with many other specialty societies, responded to the challenge and identified the top five areas for change in current oncology practice (Table 1) [8].